Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Shenzhen Hepalink Pharmaceutical Group Co Pretax Margin % Related Terms
Shenzhen Hepalink Pharmaceutical Group Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co Pretax Margin % Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co Pretax Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Pretax Margin % of 5.83% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is 54% below median its historical median of 12.67. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #549 out of 959 companies in the Drug Manufacturers industry, placing it in the top 57.2%.
Is Shenzhen Hepalink Pharmaceutical Group Co's Pretax Margin % too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Pretax Margin % of 5.83% is 54% below median its 10-year median of 12.67. The Drug Manufacturers industry median Pretax Margin % is 7.21. Shenzhen Hepalink Pharmaceutical Group Co's value of 5.83% is 19.1% below this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #549 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #549 out of 959 companies for Pretax Margin %. This places Shenzhen Hepalink Pharmaceutical Group Co in the lower half of its industry. The industry median Pretax Margin % is 7.21. Shenzhen Hepalink Pharmaceutical Group Co's value of 5.83% is 19.1% below this benchmark. While the company's 10-year median is 12.67 vs. the industry median of 7.21, Shenzhen Hepalink Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.21, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current Pretax Margin % of 5.83% is 19.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current Pretax Margin % is 5.83%, which is 54% below median its own 10-year median of 12.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Pretax Margin % of 5.83%. The stock's GF Value™ is $0.53, compared to a current price of $0.47 — trading 11.4% below its estimated fair value. The current Pretax Margin % is 5.83%, which is 54% below median its 10-year median of 12.67 and 19.1% below the Drug Manufacturers industry median of 7.21. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Pretax Margin % is 5.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 11.4% below its estimated GF Value™ of $0.53.
Key valuation signals for SHEZF:
Pretax Margin %: 5.83% (54% below median its 10-year median of 12.67)
GF Value™: $0.53 vs. price of $0.47 (11.4% below fair value)
Industry Position: 19.1% below the Drug Manufacturers median (#549 of 959)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
75GF Score
Get the complete analysis for SHEZF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
